ION expands ETF trading capabilities with Tradeweb integration
Marshall S. Stanton, SVP, Clinical & MD Affair at Artivion, INC. (NASDAQ:AORT), sold 4,993 shares of common stock on November 13, 2025, at a price of $45.858, totaling $228,968.
The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission. Following the transaction, Stanton directly owns 56,641 shares of Artivion, a company currently valued at approximately $2.11 billion.
The sale was to cover tax withholding obligations related to the vesting of restricted stock units and does not represent a discretionary transaction. According to InvestingPro data, Artivion’s stock appears to be trading above its Fair Value, with analysts setting price targets between $40 and $58. While not profitable over the last twelve months, the company is expected to become profitable this year, with revenue growing at 9.81% year-over-year.For investors interested in a deeper analysis of Artivion’s financial health and growth prospects, InvestingPro offers comprehensive Pro Research Reports with 16+ additional ProTips and extensive metrics that can help inform investment decisions.
In other recent news, Artivion Inc. reported impressive third-quarter results for 2025, with earnings per share (EPS) of $0.16, significantly surpassing the forecasted $0.03. The company also achieved revenues of $113.4 million, exceeding the anticipated $110.44 million. These results led Needham to raise its price target for Artivion to $58 from $50, maintaining a Buy rating. Similarly, Oppenheimer increased its price target to $50 from $40, while keeping an Outperform rating, following the strong earnings report. Artivion’s management responded to the robust performance by raising both its revenue and EBITDA guidance for the full year 2025. Analysts have noted the company’s 16% year-over-year revenue growth on a pro-forma, constant-currency basis. This growth exceeded both Oppenheimer’s and consensus estimates, with the former predicting $112 million and the latter $110 million. These developments reflect positively on Artivion’s financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.